Calculations - why this is a bargain buy right now!6 Aug 2021 10:49
@ 290 SP the Market Cap is 205m
Revenue is 277m
Profit 167m
Net assets 150m
Cash 92m
Debt £0
This is setup so well & incredibly undervalued as not even 1x on revenue making profit with no debt. On a US stock market this would be 800m to 1.1b market cap with these profits.
Forward looking Statement even without DHSC are strong to!
“ Looking forward, the Company expects strong growth in private testing as markets and travel re-open, which could lead to higher infection rates, and an increase in testing to return in Q4 2021, in line with Q4 2020, during the winter period. The Company also expects to see significant new growth from the launch of new products during the second half of 2021, including an expansion of its lateral flow antigen testing portfolio for both professional and home use. If demand picks up in line with expectations, the Company expects to see full year sales of approximately £100m, excluding the sales to the DHSC which are in dispute.
In the first five months of 2021, Novacyt has delivered a gross margin of over 70% and an EBITDA margin of over 40%, excluding the impact of sales to the DHSC, and the Directors are confident the Company can maintain these levels of underlying profitability for the balance of the year if volumes are in-line with its current expectations. This assumes no further sales to the DHSC for the balance of the year and no further provisions or adjustments relating to the current dispute.”
Corrupt U.K. markets